An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program
- PMID: 15717323
- DOI: 10.1002/pds.1085
An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program
Abstract
Purpose: The CDC's Anthrax Vaccine and Antibiotic Availability Program was implemented under an Investigational New Drug (IND) application to provide additional post-exposure prophylaxis for individuals potentially exposed to Bacillus anthracis in the fall of 2001. Participants were provided with two options: (1) 40 additional days of antimicrobial prophylaxis (i.e., ciprofloxacin, doxycycline, or amoxicillin); or (2) 40 additional days of antimicrobial prophylaxis plus three doses of anthrax vaccine adsorbed (AVA).
Methods: Participants were monitored for adverse events (AEs). Participants were asked to complete 2-week AE diaries for 6 weeks post-enrollment, and approximately 2 months after enrollment, active surveillance was conducted through telephone interviews with 1113 (64%) participants.
Results: A total of 1727 of approximately 10 000 previously prophylaxed persons enrolled to receive 40 additional days of antibiotics. Of these, 199 opted at enrollment to receive three doses of AVA in addition to the additional 40 days of antibiotic. Overall, 28% of participants reported at least one AE on their diaries. Results varied by surveillance mechanism, the diary data indicated differences in the proportion reporting AEs between participants receiving antibiotic only and participants receiving antibiotic and AVA. However, during the active 2-month telephone follow-up, the rates of AEs reported for both the antibiotic only and antibiotic plus AVA treatment regimens were similar. Additionally, ciprofloxacin and doxycycline had similar AE profiles, with only rigors reported significantly more often among ciprofloxacin recipients.
Conclusions: Overall, the rates of AEs experienced by all participants were acceptable given the seriousness of potential B. anthracis exposure.
Comment in
-
Lessons learned from the CDC's post-exposure prophylaxis program following the anthrax attacks of 2001.Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):389-91. doi: 10.1002/pds.1086. Pharmacoepidemiol Drug Saf. 2005. PMID: 15924332 No abstract available.
Similar articles
-
Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program.Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):880-8. doi: 10.1002/pds.1302. Pharmacoepidemiol Drug Saf. 2006. PMID: 16924600
-
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):825-40. doi: 10.1002/pds.936. Pharmacoepidemiol Drug Saf. 2004. PMID: 15386719 Review.
-
Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.Clin Infect Dis. 2003 Oct 1;37(7):905-11. doi: 10.1086/377738. Epub 2003 Sep 12. Clin Infect Dis. 2003. PMID: 13130401
-
Vaccines and bioterrorism: smallpox and anthrax.J Fam Pract. 2003 Jan;52(1 Suppl):S56-61. J Fam Pract. 2003. PMID: 12556279 Review.
-
Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.MMWR Morb Mortal Wkly Rep. 2001 Nov 30;50(47):1051-4. MMWR Morb Mortal Wkly Rep. 2001. PMID: 11808926
Cited by
-
Confronting the threat of bioterrorism: realities, challenges, and defensive strategies.Lancet Infect Dis. 2019 Jan;19(1):e2-e13. doi: 10.1016/S1473-3099(18)30298-6. Epub 2018 Oct 16. Lancet Infect Dis. 2019. PMID: 30340981 Free PMC article. Review.
-
Pediatric anthrax clinical management.Pediatrics. 2014 May;133(5):e1411-36. doi: 10.1542/peds.2014-0563. Pediatrics. 2014. PMID: 24777226 Free PMC article.
-
Interaction of occupational and personal risk factors in workforce health and safety.Am J Public Health. 2012 Mar;102(3):434-48. doi: 10.2105/AJPH.2011.300249. Epub 2011 Nov 28. Am J Public Health. 2012. PMID: 22021293 Free PMC article.
-
Mechanism of inhibition of Bacillus anthracis spore outgrowth by the lantibiotic nisin.ACS Chem Biol. 2011 Jul 15;6(7):744-52. doi: 10.1021/cb1004178. Epub 2011 May 5. ACS Chem Biol. 2011. PMID: 21517116 Free PMC article.
-
The anthrax vaccine and research: reactions from postal workers and public health professionals.Biosecur Bioterror. 2008 Dec;6(4):321-33. doi: 10.1089/bsp.2007.0064. Biosecur Bioterror. 2008. PMID: 19117431 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical